Omalizumab to prevent future asthma flare-ups before they start
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial studies whether starting omalizumab before asthma flare-ups begin can reduce how often children get worsening asthma that needs strong steroid medicine. It is for children with persistent asthma who have signs of allergic/asthma triggers and recent flare-up history.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is ages 6 to 17, and parent can consent in English (child age 7+ agrees too)
- Child has a doctor diagnosis of persistent asthma
- Child had enough recent asthma flare-ups needing oral/systemic steroids (based on a 6- or 12-month window before the next school year)
- Child shows allergy-related signs: sensitized to outdoor/indoor air allergens (perennial) and meets specific IgE or allergy measures for dosing
- Child can join during a specific fall visit when they’re currently starting a cold (URI) within 72 hours and meet test/no-new-steroid rules
- No pregnancy or breastfeeding, and able to follow birth control rules if able to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a high-dose vitamin D supplement can help preschool children have fewer acute asthma-like symptoms (coughing, wheezing, or trouble breathing) that require hospital care. It may help by supporting the immune and airway system, but you can only join if the child meets several safety and treatment criteria.
This study tests if omalizumab (Xolair), an injectable medicine that blocks allergy antibodies, can help people with food allergies tolerate small amounts of their trigger foods. It's for people with high total IgE levels who were not eligible for a related study.
This study gives a few doses of omalizumab (a medicine that blocks allergic reactions) and then does a food challenge to see if the patient can eat the food safely. It is for people who have already been prescribed this medicine for food allergy.
This trial tests whether stopping omalizumab for a short time (or using it differently) can be safe for adults with severe allergic asthma who are doing well. It may help some people avoid long-term injections, but only if asthma remains well controlled.
This trial tests if omalizumab (Xolair) can improve skin reactions in people with food allergies. It may help reduce allergic symptoms triggered by foods like peanut, egg, or milk.
This study tests if omalizumab, an allergy medicine, can help people with COPD who are allergic to common indoor allergens and have had recent flare-ups. It aims to see if reducing allergic reactions can improve COPD control.
Hear when a new Asthma in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.